MedTrace Logo

Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors

NCT05544292 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 69

Last updated 2025-08-24

No results posted yet for this study

Summary

RIMRA is a prospective, longitudinal, observational study including patients with de novo symptoms of rheumatic disease or a flare of established rheumatic disease after treatment with an immune check point inhibitor. The aim of the study is to describe the clinical presentation, disease course and outcome of rheumatic irAEs in patients treated with immune check point inhibitors.

Conditions

  • Immune-related Adverse Event

Interventions

OTHER

Antiinflammatory/DMARDs

Antiinflammatory/DMARDs

Sponsors & Collaborators

  • Oslo University Hospital

    collaborator OTHER

  • Alesund Hospital

    collaborator OTHER

  • University Hospital of North Norway

    collaborator OTHER

  • Hospital of Southern Norway Trust

    collaborator OTHER

  • Helse Nord-Trøndelag HF

    collaborator OTHER

  • Diakonhjemmet Hospital

    lead OTHER

Principal Investigators

  • Marte S Heiberg, MD, PhD · Diakonhjemmet Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-05
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05544292 on ClinicalTrials.gov